MX2019000037A - Metodos para perfilado de fragmentoma de acidos nucleicos libres de celula. - Google Patents
Metodos para perfilado de fragmentoma de acidos nucleicos libres de celula.Info
- Publication number
- MX2019000037A MX2019000037A MX2019000037A MX2019000037A MX2019000037A MX 2019000037 A MX2019000037 A MX 2019000037A MX 2019000037 A MX2019000037 A MX 2019000037A MX 2019000037 A MX2019000037 A MX 2019000037A MX 2019000037 A MX2019000037 A MX 2019000037A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- methods
- dna
- nucleic acids
- free nucleic
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 102000053602 DNA Human genes 0.000 abstract 5
- 108020004414 DNA Proteins 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 2
- 230000004077 genetic alteration Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000392 somatic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Artificial Intelligence (AREA)
- Software Systems (AREA)
- Public Health (AREA)
- Evolutionary Computation (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción contempla varios usos de ADN libre de célula. Los métodos proporcionados en la presente pueden usar información de secuencia de una manera global y de macroescala, con o sin información de variantes somáticas, para valorar un perfil de fragmentoma que puede ser representativo de un tejido de origen, enfermedad, progresión, etc. En un aspecto, en la presente se describe un método para determinar la presencia o ausencia de una anormalidad genética en fragmentos de ácido desoxirribonucleico (ADN) de ADN libre de célula obtenido de un sujeto, el método que comprende: (a) construir una distribución multiparamétrica de los fragmentos de ADN sobre una pluralidad de posiciones base en un genoma; y (b) sin tomar en cuenta una identidad base de cada posición base en un primer locus, usar la distribución multiparamétrica para determinar la presencia o ausencia de la anormalidad genética en el primer locus en el sujeto.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359151P | 2016-07-06 | 2016-07-06 | |
| US201662420167P | 2016-11-10 | 2016-11-10 | |
| US201662437172P | 2016-12-21 | 2016-12-21 | |
| US201762489399P | 2017-04-24 | 2017-04-24 | |
| PCT/US2017/040986 WO2018009723A1 (en) | 2016-07-06 | 2017-07-06 | Methods for fragmentome profiling of cell-free nucleic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000037A true MX2019000037A (es) | 2019-07-10 |
Family
ID=60913158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000037A MX2019000037A (es) | 2016-07-06 | 2017-07-06 | Metodos para perfilado de fragmentoma de acidos nucleicos libres de celula. |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP4322168A3 (es) |
| JP (3) | JP7448310B2 (es) |
| KR (1) | KR102610098B1 (es) |
| CN (1) | CN109689891B (es) |
| AU (1) | AU2017292854B2 (es) |
| BR (1) | BR112019000296A2 (es) |
| CA (1) | CA3030038A1 (es) |
| ES (1) | ES2967443T3 (es) |
| MX (1) | MX2019000037A (es) |
| SG (1) | SG11201811556RA (es) |
| WO (1) | WO2018009723A1 (es) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| AU2011255641A1 (en) | 2010-05-18 | 2012-12-06 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| JP6153874B2 (ja) | 2011-02-09 | 2017-06-28 | ナテラ， インコーポレイテッド | 非侵襲的出生前倍数性呼び出しのための方法 |
| CN103748236B (zh) | 2011-04-15 | 2018-12-25 | 约翰·霍普金斯大学 | 安全测序系统 |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| PL2912468T3 (pl) | 2012-10-29 | 2019-04-30 | Univ Johns Hopkins | Test papanicolaou pod kątem raka jajnika i endometrium |
| JP6659575B2 (ja) | 2014-04-21 | 2020-03-04 | ナテラ， インコーポレイテッド | 変異の検出および染色体分節の倍数性 |
| US20180173846A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| DK3294906T3 (en) | 2015-05-11 | 2024-08-05 | Natera Inc | Methods for determining ploidy |
| PT3967775T (pt) | 2015-07-23 | 2023-10-10 | Univ Hong Kong Chinese | Análise de padrões de fragmentação de adn sem células |
| US11286531B2 (en) | 2015-08-11 | 2022-03-29 | The Johns Hopkins University | Assaying ovarian cyst fluid |
| KR102326769B1 (ko) | 2016-03-25 | 2021-11-17 | 카리우스, 인코포레이티드 | 합성 핵산 스파이크-인 |
| CN109477138A (zh) | 2016-04-15 | 2019-03-15 | 纳特拉公司 | 肺癌检测方法 |
| WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| CA3046007A1 (en) | 2016-12-22 | 2018-06-28 | Guardant Health, Inc. | Methods and systems for analyzing nucleic acid molecules |
| WO2018137685A1 (en) | 2017-01-25 | 2018-08-02 | The Chinese University Of Hong Kong | Diagnostic applications using nucleic acid fragments |
| WO2019016353A1 (en) * | 2017-07-21 | 2019-01-24 | F. Hoffmann-La Roche Ag | CLASSIFICATION OF SOMATIC MUTATIONS FROM A HETEROGENEOUS SAMPLE |
| MX2020001575A (es) | 2017-08-07 | 2020-11-18 | Univ Johns Hopkins | Materiales y métodos para evaluar y tratar el cáncer. |
| WO2019060716A1 (en) | 2017-09-25 | 2019-03-28 | Freenome Holdings, Inc. | SAMPLE EXTRACTION METHODS AND SYSTEMS |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| WO2019147663A1 (en) * | 2018-01-24 | 2019-08-01 | Freenome Holdings, Inc. | Methods and systems for abnormality detection in the patterns of nucleic acids |
| SG11202007871RA (en) * | 2018-02-27 | 2020-09-29 | Univ Cornell | Systems and methods for detection of residual disease |
| EP3762513A1 (en) | 2018-03-08 | 2021-01-13 | St. Johns University | Circulating serum cell-free dna biomarkers and methods |
| CN112005306A (zh) * | 2018-03-13 | 2020-11-27 | 格里尔公司 | 选择、管理和分析高维数据的方法和系统 |
| US12087406B2 (en) | 2018-03-15 | 2024-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Methods using chromatin-related nucleic acid signals for performing clinical actions |
| CA3096678A1 (en) * | 2018-04-13 | 2019-10-17 | Grail, Inc. | Multi-assay prediction model for cancer detection |
| JP7455757B2 (ja) * | 2018-04-13 | 2024-03-26 | フリーノーム・ホールディングス・インコーポレイテッド | 生体試料の多検体アッセイのための機械学習実装 |
| CN112236535A (zh) | 2018-04-14 | 2021-01-15 | 纳特拉公司 | 用于借助于循环肿瘤dna的个人化检测的癌症检测和监测的方法 |
| AU2019277698A1 (en) | 2018-06-01 | 2020-11-19 | Grail, Llc | Convolutional neural network systems and methods for data classification |
| WO2020006369A1 (en) * | 2018-06-29 | 2020-01-02 | Guardant Health, Inc. | Methods and systems for analysis of ctcf binding regions in cell-free dna |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| JP7637615B2 (ja) * | 2018-09-04 | 2025-02-28 | ガーダント ヘルス， インコーポレイテッド | 無細胞核酸試料におけるアレル不均衡を検出するための方法およびシステム |
| CN112740239B (zh) * | 2018-10-08 | 2025-02-28 | 福瑞诺姆控股公司 | 转录因子分析 |
| GB201818159D0 (en) * | 2018-11-07 | 2018-12-19 | Cancer Research Tech Ltd | Enhanced detection of target dna by fragment size analysis |
| CA3118742A1 (en) * | 2018-11-21 | 2020-05-28 | Karius, Inc. | Detection and prediction of infectious disease |
| CA3118990A1 (en) | 2018-11-21 | 2020-05-28 | Karius, Inc. | Direct-to-library methods, systems, and compositions |
| US10468141B1 (en) * | 2018-11-28 | 2019-11-05 | Asia Genomics Pte. Ltd. | Ancestry-specific genetic risk scores |
| US11581062B2 (en) | 2018-12-10 | 2023-02-14 | Grail, Llc | Systems and methods for classifying patients with respect to multiple cancer classes |
| CA3123474A1 (en) * | 2018-12-19 | 2020-06-25 | The Chinese University Of Hong Kong | Cell-free dna end characteristics |
| WO2020127629A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Identification of global sequence features in whole genome sequence data from circulating nucelic acid |
| CA3122109A1 (en) * | 2018-12-21 | 2020-06-25 | Grail, Inc. | Systems and methods for using fragment lengths as a predictor of cancer |
| WO2020150258A1 (en) * | 2019-01-15 | 2020-07-23 | Luminist, Inc. | Methods and systems for detecting liver disease |
| KR20210119282A (ko) * | 2019-01-24 | 2021-10-05 | 일루미나, 인코포레이티드 | 장기 건강 및 질환을 모니터링하기 위한 방법 및 시스템 |
| ES3013495T3 (en) | 2019-01-31 | 2025-04-14 | Guardant Health Inc | Method for isolating and sequencing cell-free dna |
| US11475978B2 (en) | 2019-02-12 | 2022-10-18 | Tempus Labs, Inc. | Detection of human leukocyte antigen loss of heterozygosity |
| AU2020221847A1 (en) | 2019-02-12 | 2021-09-16 | Tempus Ai, Inc. | Detection of Human Leukocyte Antigen loss of heterozygosity |
| WO2020176659A1 (en) * | 2019-02-27 | 2020-09-03 | Guardant Health, Inc. | Methods and systems for determining the cellular origin of cell-free dna |
| EP3956466A1 (en) * | 2019-04-15 | 2022-02-23 | Natera, Inc. | Improved liquid biopsy using size selection |
| US12497662B2 (en) | 2019-04-16 | 2025-12-16 | Grail, Inc. | Systems and methods for tumor fraction estimation from small variants |
| WO2020237184A1 (en) * | 2019-05-22 | 2020-11-26 | Grail, Inc. | Systems and methods for determining whether a subject has a cancer condition using transfer learning |
| WO2020243722A1 (en) | 2019-05-31 | 2020-12-03 | Guardant Health, Inc. | Methods and systems for improving patient monitoring after surgery |
| EP3980559A1 (en) | 2019-06-06 | 2022-04-13 | Natera, Inc. | Methods for detecting immune cell dna and monitoring immune system |
| EP3997242A4 (en) * | 2019-07-09 | 2023-08-02 | The Translational Genomics Research Institute | Methods of detecting disease and treatment response in cfdna |
| WO2021041968A1 (en) * | 2019-08-28 | 2021-03-04 | Grail, Inc. | Systems and methods for predicting and monitoring treatment response from cell-free nucleic acids |
| CN110706749B (zh) * | 2019-09-10 | 2022-06-10 | 至本医疗科技（上海）有限公司 | 一种基于组织器官分化层次关系的癌症类型预测系统和方法 |
| WO2021067484A1 (en) | 2019-09-30 | 2021-04-08 | Guardant Health, Inc. | Compositions and methods for analyzing cell-free dna in methylation partitioning assays |
| WO2021072275A1 (en) * | 2019-10-11 | 2021-04-15 | Guardant Health, Inc. | Use of cell free bacterial nucleic acids for detection of cancer |
| JP7783176B2 (ja) | 2019-11-26 | 2025-12-09 | ガーダント ヘルス， インコーポレイテッド | メチル化ポリヌクレオチドの結合を改善するための方法、組成物およびシステム |
| EP4068291A4 (en) * | 2019-11-29 | 2023-12-20 | GC Genome Corporation | METHOD FOR DETECTING CHROMOSOMAL ANOMALIES USING ARTIFICIAL INTELLIGENCE |
| WO2021127208A1 (en) * | 2019-12-20 | 2021-06-24 | Accuragen Holdings Limited | Methods and systems for disease detection |
| US20230042332A1 (en) * | 2019-12-24 | 2023-02-09 | Vib Vzw | Disease Detection in Liquid Biopsies |
| US20220073977A1 (en) | 2020-02-14 | 2022-03-10 | The Johns Hopkins University | Methods and materials for assessing nucleic acids |
| US20210285042A1 (en) * | 2020-02-28 | 2021-09-16 | Grail, Inc. | Systems and methods for calling variants using methylation sequencing data |
| WO2021222828A1 (en) | 2020-04-30 | 2021-11-04 | Guardant Health, Inc. | Methods for sequence determination using partitioned nucleic acids |
| CA3179853A1 (en) | 2020-05-22 | 2021-11-25 | Diana ABDUEVA | Methods for characterizing cell-free nucleic acid fragments |
| ES2987661T3 (es) | 2020-07-10 | 2024-11-15 | Guardant Health Inc | Métodos de detección de reordenamientos genómicos utilizando ácidos nucleicos libres de células |
| WO2023282916A1 (en) | 2021-07-09 | 2023-01-12 | Guardant Health, Inc. | Methods of detecting genomic rearrangements using cell free nucleic acids |
| ES3018032T3 (en) | 2020-07-30 | 2025-05-14 | Guardant Health Inc | Methods for isolating cell-free dna |
| JP2023540221A (ja) | 2020-08-25 | 2023-09-22 | ガーダント ヘルス， インコーポレイテッド | バリアントの起源を予測するための方法およびシステム |
| US20230348997A1 (en) * | 2020-09-17 | 2023-11-02 | The Regents Of The University Of Colorado, A Body Corporate | Signatures in cell-free dna to detect disease, track treatment response, and inform treatment decisions |
| EP4222279A1 (en) | 2020-09-30 | 2023-08-09 | Guardant Health, Inc. | Methods and systems to improve the signal to noise ratio of dna methylation partitioning assays |
| EP4232599A1 (en) | 2020-10-23 | 2023-08-30 | Guardant Health, Inc. | Compositions and methods for analyzing dna using partitioning and base conversion |
| WO2022115810A1 (en) | 2020-11-30 | 2022-06-02 | Guardant Health, Inc. | Compositions and methods for enriching methylated polynucleotides |
| CN114634982A (zh) * | 2020-12-15 | 2022-06-17 | 广州市基准医疗有限责任公司 | 一种检测多核苷酸变异的方法 |
| EP4015650A1 (en) * | 2020-12-18 | 2022-06-22 | Nipd Genetics Biotech Limited | Methods for classifying a sample into clinically relevant categories |
| EP4267757A1 (en) | 2020-12-23 | 2023-11-01 | Guardant Health, Inc. | Methods and systems for analyzing methylated polynucleotides |
| EP4291679A1 (en) | 2021-02-12 | 2023-12-20 | Guardant Health, Inc. | Methods and compositions for detecting nucleic acid variants |
| EP4314329A1 (en) | 2021-03-25 | 2024-02-07 | Guardant Health, Inc. | Methods and compositions for quantifying immune cell dna |
| WO2022248844A1 (en) * | 2021-05-24 | 2022-12-01 | University Of Essex Enterprises Limited | Method and system for identifying genomic regions with condition sensitive occupancy/positioning of nucleosomes and/or chromatin |
| KR20220160805A (ko) * | 2021-05-28 | 2022-12-06 | 한국과학기술원 | 조직 특이적 조절지역의 무세포 dna 분포를 이용한 인공지능 기반 암 조기진단 방법 |
| CN113838533B (zh) * | 2021-08-17 | 2024-03-12 | 福建和瑞基因科技有限公司 | 一种癌症检测模型及其构建方法和试剂盒 |
| CA3236814A1 (en) * | 2021-11-17 | 2023-05-25 | Maximilian Diehn | Systems and methods for gene expression and tissue of origin inference from cell-free dna |
| KR102884871B1 (ko) * | 2022-01-26 | 2025-11-11 | 권창혁 | 암 판별 장치 및 암 판별 방법 |
| JP2025513786A (ja) | 2022-04-07 | 2025-04-30 | ガーダント ヘルス， インコーポレイテッド | 無細胞核酸分子のメチル化状態に基づいた腫瘍の存在の検出 |
| EP4532762A1 (en) * | 2022-06-02 | 2025-04-09 | The Board Of Trustees Of The Leland Stanford Junior University | Single molecule sequencing and methylation profiling of cell-free dna |
| EP4547857A1 (en) | 2022-06-30 | 2025-05-07 | Guardant Health, Inc. | Enrichment of aberrantly methylated dna |
| US20240043935A1 (en) * | 2022-07-29 | 2024-02-08 | Centre For Novostics Limited | Epigenetics analysis of cell-free dna |
| JP2025532196A (ja) | 2022-09-27 | 2025-09-29 | ガーダント ヘルス， インコーポレイテッド | 免疫細胞ｄｎａを定量するための方法 |
| CN116052768A (zh) * | 2022-10-08 | 2023-05-02 | 南京世和基因生物技术股份有限公司 | 恶性肺结节筛查基因标志物、筛查模型的构建方法和检测装置 |
| EP4638782A2 (en) | 2022-12-22 | 2025-10-29 | Guardant Health, Inc. | Integrated targeted and whole genome somatic and dna methylation sequencing workflows |
| WO2024137880A2 (en) | 2022-12-22 | 2024-06-27 | Guardant Health, Inc. | Methods involving methylation preserving amplification with error correction |
| WO2024233502A1 (en) | 2023-05-05 | 2024-11-14 | Guardant Health, Inc. | Cell-free dna blood-based test for cancer screening |
| WO2025019370A1 (en) * | 2023-07-14 | 2025-01-23 | Natera, Inc. | Methods for assaying circulating tumor dna |
| WO2025029475A1 (en) | 2023-07-28 | 2025-02-06 | Guardant Health, Inc. | Methods to enrich nucleotide variants by negative selection |
| WO2025038399A1 (en) | 2023-08-11 | 2025-02-20 | Guardant Health, Inc. | Methylated enrichment methods for single-molecule genetic and epigenetic sequencing |
| CN117230165A (zh) * | 2023-09-01 | 2023-12-15 | 深圳湾实验室 | 一种无创产前检测胎儿染色体拷贝数异常的优化方法 |
| WO2025064706A1 (en) | 2023-09-19 | 2025-03-27 | Guardant Health, Inc. | Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules |
| WO2025076452A1 (en) | 2023-10-06 | 2025-04-10 | Guardant Health, Inc. | Detecting tumor-related information based on methylation status of cell-free nucleic acid molecules |
| WO2025207817A1 (en) | 2024-03-26 | 2025-10-02 | Guardant Health, Inc. | Method of determining the likelihood of a disease by combining biomarkers and imaging |
| WO2025208044A1 (en) | 2024-03-28 | 2025-10-02 | Guardant Health, Inc. | Methods for cancer detection using molecular patterns |
| WO2025205006A1 (ja) * | 2024-03-29 | 2025-10-02 | ソニーグループ株式会社 | 分析方法、クロマチン状態を分類する方法、がん検査方法、分析システム、がん又は微小残存病変の検査システムおよび分析キット |
| WO2025235889A1 (en) | 2024-05-10 | 2025-11-13 | Guardant Health, Inc. | Methods involving multiplexed pooled pcr |
| WO2025250544A1 (en) | 2024-05-31 | 2025-12-04 | Guardant Health, Inc. | Methods for analyzing chromatin architecture in tissue to boost detection of cancer associated signals in cell-free dna |
| CN120334449B (zh) * | 2025-06-20 | 2025-09-05 | 陕西右任故里茯砖茶股份有限公司 | 基于液相色谱的茯砖茶中金花菌发酵检测方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2545757C2 (ru) | 2008-10-30 | 2015-04-10 | Сантр Де Решерш Пюблик Де Ля Сантэ | Биомаркеры |
| CN101901345B (zh) * | 2009-05-27 | 2013-02-27 | 复旦大学 | 一种差异蛋白质组学的分类方法 |
| US11322224B2 (en) * | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| EP2426217A1 (en) * | 2010-09-03 | 2012-03-07 | Centre National de la Recherche Scientifique (CNRS) | Analytical methods for cell free nucleic acids and applications |
| KR101974492B1 (ko) * | 2011-07-26 | 2019-05-02 | 베리나타 헬스, 인코포레이티드 | 샘플 중 상이한 이수성의 존재 또는 부재를 결정하는 방법 |
| WO2013052913A2 (en) | 2011-10-06 | 2013-04-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US9367663B2 (en) * | 2011-10-06 | 2016-06-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US20150057948A1 (en) | 2012-02-16 | 2015-02-26 | Oxford Nanopore Technologies Limited | Analysis of measurements of a polymer |
| JP6411995B2 (ja) * | 2012-03-13 | 2018-10-24 | ザ チャイニーズ ユニバーシティー オブ ホンコン | 非侵襲的出生前診断のために大量並列シークエンシング・データを分析する方法 |
| CN103374518B (zh) * | 2012-04-12 | 2018-03-27 | 维里纳塔健康公司 | 拷贝数变异的检测和分类 |
| US10497461B2 (en) | 2012-06-22 | 2019-12-03 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US20160040229A1 (en) * | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| EP4424826A3 (en) * | 2012-09-04 | 2024-11-27 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US20130309666A1 (en) * | 2013-01-25 | 2013-11-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| HK1222684A1 (zh) * | 2013-03-15 | 2017-07-07 | 夸登特健康公司 | 检测稀有突变和拷贝数变异的系统和方法 |
| CA2915626A1 (en) * | 2013-06-17 | 2014-12-24 | Verinata Health, Inc. | Method for determining copy number variations in sex chromosomes |
| US9499870B2 (en) * | 2013-09-27 | 2016-11-22 | Natera, Inc. | Cell free DNA diagnostic testing standards |
| SG11201604923XA (en) | 2013-12-28 | 2016-07-28 | Guardant Health Inc | Methods and systems for detecting genetic variants |
| US10318704B2 (en) * | 2014-05-30 | 2019-06-11 | Verinata Health, Inc. | Detecting fetal sub-chromosomal aneuploidies |
| KR102696857B1 (ko) | 2014-07-25 | 2024-08-19 | 유니버시티 오브 워싱톤 | 무세포 dna를 생성하는 조직 및/또는 세포 유형을 결정하는 방법 및 이를 사용하여 질환 또는 장애를 확인하는 방법 |
| WO2016094853A1 (en) * | 2014-12-12 | 2016-06-16 | Verinata Health, Inc. | Using cell-free dna fragment size to determine copy number variations |
-
2017
- 2017-07-06 EP EP23202039.6A patent/EP4322168A3/en active Pending
- 2017-07-06 JP JP2018568937A patent/JP7448310B2/ja active Active
- 2017-07-06 EP EP17824931.4A patent/EP3481966B1/en active Active
- 2017-07-06 SG SG11201811556RA patent/SG11201811556RA/en unknown
- 2017-07-06 CA CA3030038A patent/CA3030038A1/en active Pending
- 2017-07-06 WO PCT/US2017/040986 patent/WO2018009723A1/en not_active Ceased
- 2017-07-06 BR BR112019000296-0A patent/BR112019000296A2/pt not_active Application Discontinuation
- 2017-07-06 KR KR1020197003420A patent/KR102610098B1/ko active Active
- 2017-07-06 MX MX2019000037A patent/MX2019000037A/es unknown
- 2017-07-06 AU AU2017292854A patent/AU2017292854B2/en active Active
- 2017-07-06 ES ES17824931T patent/ES2967443T3/es active Active
- 2017-07-06 CN CN201780054825.3A patent/CN109689891B/zh active Active
-
2021
- 2021-10-26 JP JP2021174556A patent/JP2022025101A/ja not_active Withdrawn
-
2024
- 2024-06-05 JP JP2024091417A patent/JP2024119898A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2967443T3 (es) | 2024-04-30 |
| SG11201811556RA (en) | 2019-01-30 |
| BR112019000296A2 (pt) | 2019-04-16 |
| JP2024119898A (ja) | 2024-09-03 |
| KR102610098B1 (ko) | 2023-12-04 |
| WO2018009723A1 (en) | 2018-01-11 |
| KR20190026837A (ko) | 2019-03-13 |
| EP3481966B1 (en) | 2023-11-08 |
| EP3481966A4 (en) | 2019-08-07 |
| JP2022025101A (ja) | 2022-02-09 |
| EP3481966A1 (en) | 2019-05-15 |
| JP2019531700A (ja) | 2019-11-07 |
| CA3030038A1 (en) | 2018-01-11 |
| AU2017292854B2 (en) | 2023-08-17 |
| CN109689891A (zh) | 2019-04-26 |
| AU2017292854A1 (en) | 2019-01-24 |
| EP4322168A3 (en) | 2024-05-15 |
| CN109689891B (zh) | 2024-06-18 |
| EP4322168A2 (en) | 2024-02-14 |
| JP7448310B2 (ja) | 2024-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000037A (es) | Metodos para perfilado de fragmentoma de acidos nucleicos libres de celula. | |
| SG10201906673WA (en) | Artificial nucleic acid molecules | |
| EP4269577A3 (en) | Nucleobase editors and uses thereof | |
| FI3604532T3 (fi) | Uusia crispr-entsyymejä ja järjestelmiä | |
| MX2015017110A (es) | Integracion dirigida. | |
| AU2017257225A1 (en) | Allele editing and applications thereof | |
| HK1258869A1 (zh) | 寡核酸变体文库及其合成 | |
| BR112015012375A2 (pt) | modificação e regulação de genoma à base de crispr | |
| EP4428863A3 (en) | Methods and compositions for determining ploidy | |
| EP4235677A3 (en) | Processes and systems for nucleic acid sequence assembly | |
| WO2012094492A3 (en) | Combinatorial dna taggants and methods of preparation and use thereof | |
| CA2983023A1 (en) | Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids | |
| SG10201805815YA (en) | Rna-guided gene drives | |
| GB201808146D0 (en) | Stereospecific Linkages in RNA Editing Oligonucleotides | |
| WO2014145820A3 (en) | Multiple tagging of long dna fragments | |
| MX2022009242A (es) | Producto en desarrollo de analisis de secuenciacion de alineacion y variante. | |
| EA201992795A1 (ru) | Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе | |
| EP3699280A3 (en) | Novel cas9 systems and methods of use | |
| MX2018001617A (es) | Composiciones de crispr-cas9 diseñados y metodos de uso. | |
| NZ728437A (en) | Methods for increasing cas9-mediated engineering efficiency | |
| EP4556564A3 (en) | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof | |
| WO2014116729A3 (en) | Haplotying of hla loci with ultra-deep shotgun sequencing | |
| WO2015200893A3 (en) | Methods of analyzing nucleic acids from individual cells or cell populations | |
| GB2511690A (en) | Detecting malware using stored patterns | |
| SA516371691B1 (ar) | Dna طرق وتركيبات لتحديد صورة تحليلية لـ |